Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

NCT07723703 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukaemia
High Risk Myelodysplastic Syndrome

Interventions

DRUG: AMX-883
DRUG: Posaconazole

Sponsor

Amphista Therapeutics Ltd